The HIV, Hepatitis, and Related Conditions Programs (HHRC) in the Veterans Health Administration (VA) is working to improve care for viral hepatitis and liver disease. The VA has seen many recent accomplishments in the treatment and cure of Veterans in VA care with hepatitis C and look to build on these successes for Veterans with hepatitis B and advanced liver disease (ALD).
Liver Cancer is one of the few cancers whose rates in the US and around the world are rising instead of falling. Interventional radiology and interventional oncology therapies are essential ensuring that patients with liver cancer are diagnosed as early as possible so that they have every innovative option for survival available to them.
NASH has been called a “hidden epidemic.” Millions of people are at risk, yet people with the disease show no symptoms until the very late stages. Diagnosing the disease is also difficult as it can take decades to progress to advanced fibrosis and cirrhosis, and it can only be diagnosed with an invasive and painful liver biopsy. While there is a lot we don’t know about NASH, there are many things we do know.
As we gather in gratitude this Thanksgiving, let us remember to give thanks for such “livers” in the world: Individuals who work selflessly and tirelessly—often quietly and away from the limelight—toward the betterment of their fellow human beings.
Statistics show that as many as one-third of adults living with a chronic illness are at greater risk of contracting the potentially deadly pneumococcal disease. Worse, if a person living with liver disease contracts pneumococcal disease, the long-term potential for worsening of their disease is elevated.
On the eve of ICER’s public meeting to discuss its evaluation of these treatments, National Pharmaceutical Council President Dan Leonard sat down with Ms. Cryer to ask her thoughts about ICER, value assessments and how patients can become more engaged in these evaluations.
Health insurers, public and private, should support the provision of care that taxpayers, employers – people – find valuable to optimizing health. However, all too often payer perspectives don’t align with those of patients, caregivers, and clinicians.
We, the hepatitis community, are at a critical juncture. We have a global strategy, we have the tools, but to ensure viral hepatitis is eliminated by 2030, we need to strengthen our call and join together under one banner, one voice – and this voice is NOhep.
As our nation’s health care system reforms, stomping out stigma is a key factor to ensure our system transforms into one that preserves, protects and bolsters the health, wellness and life opportunities of all who access health care services.
One of Astellas’ foundational areas of expertise and leadership is organ transplantation – and as we strive to build on our heritage and develop new medicines for cancer, immunologic conditions and other areas of unmet medical needs, our efforts can only be enhanced by our work with GLI.
One of the world's leading patient innovators, Robin Farmanfarmaian, shares with us a necessary approach to the shortage of solid organs for transplantation. What was formerly science fiction, is now a reality!